Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Fuji Inks Deal with Daiichi on Ranmark Biosimilar, Now Plans 2026 Launch
November 4, 2025
- Otsuka Snags APAC Rights to 4DMT’s AMD Gene Therapy
November 4, 2025
- Lenvima-Keytruda Combo’s Liver Cancer Trial Halted after OS Miss
October 31, 2025
- Boehringer Bags Rights to Kyowa Kirin’s Preclinical Autoimmune Program
October 31, 2025
- Espha’s Velcade AG Wins Approval for Mantle Cell Lymphoma
October 31, 2025
- MSD Files for Keytruda Label Expansion in Ovarian Cancer
October 31, 2025
- Astellas Beats H1 Forecast on Strategic Product Growth, Cost Controls
October 31, 2025
- Vyvanse Generics Drag Takeda Earnings; FY2025 Outlook Trimmed
October 31, 2025
- Pfizer Resumes Supply of Smoking Cessation Pill Champix after 4 Years
October 31, 2025
- Ono’s Sales Rise 7% on Overseas Growth of Qinlock, Romvimza
October 31, 2025
- Leqembi’s April-September Sales at 41.1 Billion Yen: Eisai
October 31, 2025
- TMS Founder Sees “Ray of Hope” in Novel Stroke Drug TMS-007
October 31, 2025
- Jardiance Dominates September Detailing Rankings with Five Wins: Intage
October 31, 2025
- MSD Launches 21-Valent Pneumococcal Vaccine Capvaxive in Japan
October 30, 2025
- AbbVie Files Skyrizi for Pediatric Dosage in Japan
October 30, 2025
- LifeScan Japan Taps AI to Fast-Track Sales Force Development, Draws Interest from Pharma
October 29, 2025
- J-TEC, AlliedCel Ink Service Contract for T-Cell Therapy Production
October 29, 2025
- Japan Gives Orphan Tags for Kyowa Kirin’s Gene Therapy, Cuorips’ Cell Sheet
October 29, 2025
- NEC Crafts Data Platform to Advance Personalized Cancer Vaccine Program
October 28, 2025
- Shionogi Sees Flat 1H Results, Gains Domestic Support from Torii
October 28, 2025
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…